Fuctional Analyses of Autoimmune Disease Variants

$315,445P01FY2014AINIH

Yale University, New Haven CT

Investigators

Linked publications, trials & patents

Paper 38980198 Paper 38916965 Paper 38916955 Paper 38464315 Paper 38374298 Paper 38354701 Paper 38012416 Paper 37432393 Paper 37344597 Paper 37197653 Paper 36754020 Paper 36634138 Paper 36596896 Paper 36516268 Paper 36514045 Paper 36495445 Paper 36250467 Paper 36070768 Paper 36068310 Paper 35732977 Paper 35603182 Paper 35467979 Paper 35437326 Paper 35301508 Paper 35275752 Paper 35177831 Paper 35142369 Paper 35064122 Paper 34875227 Paper 34813505 Paper 34739340 Paper 34642316 Paper 34569985 Paper 34216539 Paper 34140679 Paper 34127967 Paper 34108686 Paper 34040149 Paper 34006473 Paper 33651881 Paper 33651880 Paper 33645548 Paper 33601411 Paper 33239433 Paper 33238123 Paper 33170805 Paper 33168576 Paper 33140047 Paper 33053333 Paper 33045061 Paper 33039897 Paper 32977183 Paper 32948672 Paper 32907939 Paper 32668241 Paper 32610128 Paper 32269065 Paper 32251406 Paper 32199912 Paper 31995767 Paper 31974523 Paper 31745340 Paper 31676858 Paper 31676122 Paper 31563464 Paper 31427603 Paper 31118290 Paper 31080134 Paper 31040105 Paper 31028635 Paper 30824481 Paper 30709909 Paper 30674677 Paper 30559390 Paper 30374130 Paper 30135581 Paper 29899446 Paper 29871632 Patent 9580684 Patent 9457080 Patent 9402899 Patent 9073994 Patent 9067999 Patent 8728474 Patent 8329660 Patent 8168179 Patent 7741271 Patent 7722868 Patent 7709214 Patent 7700301 Patent 7638492 Patent 7635757 Patent 7595048 Patent 7432059 Patent 7105328 Patent 7101550 Patent 7038013 Patent 6936704 Patent 6808710 Patent 5830380

Abstract

The project, Functional Analyses of Autoimmune Disease Variants, is focused on three type 1 diabetes (T1D) susceptibility loci, CTLA4, PTPN22 and CD226 in humans and in mice. T1D is a major disease of children with an unexplained steady rise in incidence and increasing numbers of children diagnosed under age 5 years. The research proposed is fully integrated into the PPG activities and goals, and provides a platform to continue the highly productive, interdependent and synergistic collaboration amongst the PIs in Cambridge and Boston aimed at understanding the biological effects of T1D and autoimmune disease gene variants (that we have identified using genetic mapping). TlD gene variants will be studied ex vivo using fresh blood samples from a major resource of genetically-selectable, local healthy volunteers (the Cambridge BioResource) and in vivo, in precisely engineered NOD mouse models of T1D. The Ctla4, Ptpn22 and Cd226 KO alleles will be used to develop NOD strains to model human T1D. A mouse Ptpn22 variant that increases T1D will be a focus of mechanistic studies on the PTPN22 gene, which is part of a molecular pathway that affects multiple human autoimmune diseases. T cells having the susceptibility allele at Ptpn22 have a higher threshold of activation and at a population level fewer of the cells produce IL-2 when stimulated ex vivo. Since both human and mouse gene variants in the IL-2 pathway affect T1D susceptibility, experiments to study gene-gene interactions between the PTPN22 and IL-2 pathways in both species are proposed. Preliminary data indicate that the susceptibility allele at CTLA4, which decreases the expression of soluble CTLA-4, reduces the probability that Tregs will be activated. Overexpression of soluble CTLA-4 in primary T cells and cell lines will be one approach used to study the mechanism by which soluble CTLA-4 affects early events in T cell activation. Since variants at both the PTPN22 and CTLA-4 genes are proposed to alter T cell activation, gene-gene interactions between the PTPN22 and CTLA-4 pathways in both humans and mice will be investigated.

View original record on NIH RePORTER →